JPRN-UMIN000003190已完成1 期
Cancer Vaccine Therapy using Epitope Peptide Restricted to HLA-A*02 (URLC10) in Patients with Non-small Cell Lung Cancer Refractory to Standard Therapy (Phase I study) - Cancer Vaccine Therapy using Epitope Peptide Restricted to HLA-A*02 (URLC10) in Patients with Refractory Non-small Cell Lung Cancer
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 9
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Active and uncontrolled cardiac disease (i.e. coronary syndromes, arrhythmia) 2. Myocardial infarction within six months before entry 3. Breastfeeding and Pregnancy (woman of child bearing potential) 4. Active and uncontrolled infectious disease 5. Concurrent treatment with steroids or immunosuppressing agent 6. Other malignancy requiring treatment 7. Non-cured traumatic wound 8. Decision of unsuitableness by principal investigator or physician-in-charge
研究者
相似试验
已完成
1 期
Cancer Vaccine Therapy using Epitope Peptide Restricted to HLA-A*24 (CDCA1,KIF20A) in Patients with Small Cell Lung Cancer Refractory to Standard Therapy (Phase I study).Small Cell Lung CancerJPRN-UMIN000003191Shiga University of Medical Science9
已完成
1 期
Cancer Vaccine Therapy using Epitope Peptide Restricted to HLA-A*24 (URLC10,CDCA1,KIF20A) in Patients with Non-small Cell Lung Cancer Refractory to Standard Therapy (Phase I study)on-small Cell Lung CancerJPRN-UMIN000003189Shiga University of Medical Science18
已完成
1 期
Cancer vaccine therapy using epitope peptide from CDH3 restricted to HLA-A*2402 with gemcitabine chemotherapy in patients with unresectable advanced pancreatic cancer (Phase I study)pancreatic cancerJPRN-UMIN000005549Sapporo Medical University9
已完成
1 期
Cancer vaccine therapy using epitope peptide from KIF20A restricted to HLA-A*24 in patients with pancreatic cancer refractory to standard therapy (Phase I/II study)pancreatic cancerJPRN-UMIN000004919Chiba Tokushukai Hospital30
已完成
1 期
Cancer peptide vaccine therapy for patients with advanced metastatic colorectal cancer. Phase I/II clinical trial.Colorectal cancerJPRN-UMIN000004945Tokai University School of Medicine20